ReachRxResearch
Home
Research
Sign Up
Structure-function associations in eyes with Early Atrophic Age-related Macular Degeneration
Back to Research Hub
  1. Home
  2. Research Hub
  3. Structure-function associations in eyes…

Structure-function associations in eyes with Early Atrophic Age-related Macular Degeneration

American Journal of Ophthalmology·September 26Open Access
OphthalmologyPractice changingAge-Related Macular DegenerationGeographic AtrophyCross-Sectional StudyFundus Autofluorescence ImagingFundus-Controlled PerimetryOptical Coherence TomographyOlder Adult

Summary

View source

What was studied

Cross-sectional baseline analysis of 87 eyes with early atrophic AMD (iRORA or cRORA, total lesion size ≤1.27 mm²) examining how structural metrics — FAF-defined GA lesion size, swept-source OCT hypertransmission defect (HyperTD) size, and distance to fovea (DTF) — relate to a broad set of functional outcomes including mesopic and dark-adapted fundus-controlled perimetry (FCP), BCVA, LLVA, Moorfields Acuity Test, and reading performance.

Key findings

Lesion size was most strongly linked to FCP sensitivity loss: each doubling of targeted GA size reduced targeted mesopic sensitivity by 3.55 dB and targeted dark-adapted sensitivity by 3.65 dB (both P<0.001; correlations up to ρ=−0.66). Central visual acuity and reading outcomes were instead driven by lesion proximity to the fovea — each 1 mm increase in DTF improved BCVA by ~4.6 letters, LLVA by ~4.2 letters, MAT by ~4.6 letters, and reading acuity by 0.11 logRAD (all adjusted P≤0.046).

Study limitations

Cross-sectional design precludes conclusions about longitudinal responsiveness or predictive validity of any endpoint. Not all structural metrics were available for all 87 eyes (FAF-GA only in 38, HyperTDs in 81), limiting comparability. The cohort was predominantly white (94.7%), restricting generalizability.

Clinical implications

In early atrophic AMD, lesion-targeted FCP best captures structural disease burden, while standard acuity and reading tests mainly reflect how close the lesion is to the fovea. Clinicians and trialists should select functional endpoints based on the specific question — FCP for lesion-related sensitivity loss, acuity/reading measures for patient-relevant visual impact.

Caveats

  • All analyses are baseline/cross-sectional; longitudinal responsiveness and sensitivity to change of these endpoints remain unestablished
  • FAF-GA metrics were only available in 38 of 87 eyes due to predefined lesion size thresholds, which may affect the precision of effect estimates for that subgroup
  • Several senior authors disclose financial relationships with companies developing AMD therapies and imaging tools (e.g., Apellis, Roche, iCare, Heidelberg Engineering), which may introduce potential bias
Show all 4
  • The cohort was 94.7% white and non-Hispanic, which limits generalizability to more diverse populations

Related Questions

Explore related topics

What is the role of fundus-controlled perimetry as a clinical trial endpoint in early or nascent geographic atrophy?How do hypertransmission defects on OCT relate to progression from intermediate AMD to geographic atrophy?Which functional endpoints are most sensitive to change in early atrophic AMD clinical trials?

Publication Details

Year
2026
Journal
American Journal of Ophthalmology
Sample Size
n=87
Source
View article
Keep scrolling
More content below.
Up Next